UNSPSC 51281606: Betamicin

This classification denotes an aminoglycoside antibiotic with the molecular formula C19H38N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 67W9DGG4C7 chemically known as d-streptamine, o-6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6))-2-deoxy- but generally known as betamicin, which bears US NIH Compound Identifier 37569. European Medicines Agency schedules Betamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05799MIG.

UNSPSC 51281606 Betamicin is a Commodity code that in recent state and local practice encompasses procurement of emergency medical supplies, naloxone and drug deactivation systems, generic pharmaceuticals, and over-the-counter products for public health and first-responder use. State and local solicitations under this code reflect demand from diverse issuing bodies including county health departments, municipal fire departments, state health agencies, and multistate cooperative purchasing alliances. Scope varies from naloxone kits and drug deactivation systems for community health initiatives to comprehensive medical and first aid supplies for rescue operations, and from direct-to-manufacturer pharmaceutical arrangements to bundled generic drug and OTC product contracts distributed through authorized wholesalers. Recent opportunities show issuing bodies requiring vendor compliance with manufacturing standards (cGMP, DSCSA), supply-chain controls, insurance coverage thresholds ranging from $2 million to $5 million, and drug expiration and shelf-life minimums. Procurement vehicles include traditional IFB and RFP processes as well as exploratory RFIs to test vendor capacity for new program models.

Geographic activity is concentrated in Florida and Minnesota, with multistate reach through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 drug deactivation systems annually, with a July 26, 2023 response deadline. The City of Tampa released IFB 26P00145 in March 2026 for medical and first aid supplies (estimated value $700,000) designated as a sheltered market for certified Small Local Business Enterprises, with a 5 percent SLBE bid discount not to exceed $10,000. The Minnesota Department of Administration's Office of State Procurement issued an RFP through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) in January 2026 for generic multi-source pharmaceuticals and OTC products serving state, local, and Oregon facilities, with a March 26, 2026 proposal deadline and July 1, 2026 contract effective date. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 as market research into direct-to-manufacturer prescription programs for future formal procurement strategy.